Psyence Biomedical Ltd. (PBM) is an innovative biotechnology company focused on harnessing the therapeutic potential of psychedelic compounds to address mental health and wellness challenges. The company employs a vertically integrated model, encompassing the cultivation, formulation, and clinical research of psilocybin and other psychedelics, which allows for thorough control over its product development processes. With a robust intellectual property portfolio and a progressive clinical pipeline, Psyence is strategically positioned to leverage the increasing acceptance of psychedelic therapies in the healthcare marketplace, aiming to deliver effective solutions that meet the urgent needs of patients.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-6.23M |
| Operating Margin | 0.00% |
| Return on Equity | -58.60% |
| Return on Assets | -31.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.39 |
| Price-to-Book | 0.80 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.81M |
| Float | $2.61M |
| % Insiders | 2.97% |
| % Institutions | 9.72% |
Volatility is currently contracting
Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built
MINNEAPOLIS--(BUSINESS WIRE)--Tredium Solutions, a provider of pharmacy benefit management (PBM) technologies, has been selected to support the administration of Scripius' commercial, Medicare, and Medicaid pharmacy benefit programs. Through this collaboration, Tredium will provide its claims platform to support accurate and reliable processing for Scripius and the customers it serves. Scripius empowers health plans, health systems, and self-funded employers to better manage rising pharmacy cos.
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network
Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain
Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the expansion of its clinical site network in Australia from three to five sites supporting its ongoing clinical activities.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PBM and any ticker you trade — then tracks every position and per-strategy win rate.
